Home › Companies › Revolution Medicines, Inc. › 2025-2026

Revolution Medicines, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Revolution Medicines, Inc.’s Form 8-K, filed 2026-06-22 (Item 5.07 on EDGAR). Page generated 04 October 2026.

8Reported items
527Asset managers
2,571Fund votes
2026-06-18Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Revolution Medicines, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Revolution Medicines, Inc.

These tallies are Revolution Medicines, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Revolution Medicines, Inc. — official shareholder meeting results, meeting held 2026-06-18
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Alexis Borisy	127,181,172	--	--	33,660,532	20,813,641	Majority: yes
Elect Director: Mark A. Goldsmith, M.D., Ph.D.	157,681,628	--	--	3,160,076	20,813,641	Majority: yes
Proposal 2 . The Company's stockholders ratified the appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal y	181,309,783	206,306	139,256	--	--	Majority: yes
As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal. Proposal 3 .	155,110,825	5,554,146	176,733	--	20,813,641	Majority: yes

Source: Revolution Medicines, Inc., Form 8-K, filed with the SEC on 2026-06-22 — read the filing on EDGAR.

How asset managers voted at the Revolution Medicines, Inc. 2025-2026 meeting

Each item below shows how the 527 asset managers that disclosed a Revolution Medicines, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Revolution Medicines, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").

SECTION 14A SAY-ON-PAY VOTES

Combines 11 wordings of this item as funds reported it.

97% fund support · no official result

FOR 97%

The 495 asset managers below cast 97% of the shares they voted on this item FOR (181,927,423 for, 6,187,766 against).

FOR: 181,927,423 (96.7%)AGAINST: 6,187,766 (3.3%)ABSTAIN: 11,719 (0.0%)NOT VOTED: 2,837 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as di” at Revolution Medicines, Inc., 2025-2026
Asset manager	For	Against	Vote
Janus Henderson	21,654,005	9,898	For
Vanguard	20,828,940	13	For
Fidelity	20,060,897	1,279	For
FARALLON CAPITAL MANAGEMENT, L.L.C.	14,135,270	0	For
BlackRock	10,931,892	28,659	For
T. Rowe Price	6,294,823	126,705	For
Darwin Global Management, Ltd.	5,779,848	0	For
Paradigm Biocapital Advisors LP	5,094,491	0	For
JANUS INVESTMENT FUND	5,021,654	0	For
Wellington	4,408,510	0	For
Nextech Invest Ltd.	4,010,774	0	For
State Street	3,962,022	41,323	For
Charles Schwab	3,724,968	0	For
BVF INC/IL	3,581,782	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,539,327	0	For
GV Management Company, L.L.C.	2,946,619	0	For
Casdin Capital, LLC	2,577,333	0	For
Woodline Partners LP	2,276,903	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	2,256,108	0	For
Polar Capital Holdings Plc	2,144,954	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,088,274	0	For
Capital Group	0	1,610,200	Against
Caligan Partners LP	1,583,652	0	For
Holocene Advisors, LP	1,407,344	0	For
Rock Springs Capital Management LP	1,246,216	0	For

Showing the 25 largest of 495 asset managers. See all 495 in the interactive database.

2. To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; and

AUDIT-RELATEDMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 181,309,783AGAINST: 206,306

Revolution Medicines, Inc.’s own tally for this item (“Proposal 2 . The Company's stockholders ratified the appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Comp”): 181,309,783 for, 206,306 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 200,178,626 outstanding shares: 91% for, 0.2% against (91% of the company cast a for/against vote).

The 118 asset managers below cast 99.9% of the shares they voted on this item FOR (52,167,128 for, 26 against).

FOR 99.9%

FOR: 52,167,128 (100.0%)AGAINST: 26 (0.0%)ABSTAIN: 850 (0.0%)NOT VOTED: 235 (0.0%)

Largest asset managers voting on “To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoope” at Revolution Medicines, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	19,347,008	0	For
Fidelity	9,665,843	0	For
JANUS INVESTMENT FUND	5,021,654	0	For
BlackRock	4,194,817	0	For
T. Rowe Price	2,563,078	0	For
Charles Schwab	1,843,991	0	For
State Street	940,871	26	For
Columbia Threadneedle	869,224	0	For
Capital Group	794,687	0	For
Lord Abbett	707,700	0	For
Franklin Custodian Funds	400,000	0	For
Dimensional	350,840	0	For
Victory Capital	324,634	0	For
TIAA	313,907	0	For
FRANKLIN STRATEGIC SERIES	287,036	0	For
JANUS ASPEN SERIES	271,217	0	For
Invesco	260,273	0	For
MUTUAL FUND SERIES TRUST	257,218	0	For
American Century	239,067	0	For
MARSICO INVESTMENT FUND	219,460	0	For
Jackson National	219,172	0	For
Goldman Sachs	205,969	0	For
MFS	187,214	0	For
Bridge Builder Trust	140,975	0	For
Equitable	137,144	0	For

Showing the 25 largest of 118 asset managers. See all 118 in the interactive database.

3. To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Alexis Borisy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD 21%

FOR: 127,181,172WITHHELD: 33,660,532

Revolution Medicines, Inc.’s own tally for this item (“Elect Director: Alexis Borisy”): 127,181,172 for, 33,660,532 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 200,178,626 outstanding shares: 64% for, 17% withheld (80% of the company cast a for/withheld vote).

The 117 asset managers below cast 100% of the shares they voted on this item FOR (48,017,756 for, 0 against).

FOR 92%8%

FOR: 48,017,756 (92.0%)ABSTAIN: 4,156,067 (8.0%)NOT VOTED: 235 (0.0%)

Largest asset managers voting on “To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his suc” at Revolution Medicines, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	19,352,024	10,694	For
Fidelity	9,665,843	0	For
JANUS INVESTMENT FUND	4,020,158	1,001,496	For
BlackRock	4,194,817	0	For
T. Rowe Price	2,563,078	0	For
Charles Schwab	1,843,991	0	For
State Street	1,809	939,088	Abstain
Columbia Threadneedle	869,224	0	For
Capital Group	794,687	0	For
Lord Abbett	707,700	0	For
Franklin Custodian Funds	400,000	0	For
Dimensional	0	350,840	Abstain
Victory Capital	370	324,264	Abstain
TIAA	313,907	0	For
FRANKLIN STRATEGIC SERIES	287,036	0	For
JANUS ASPEN SERIES	265,540	5,677	For
Invesco	260,273	0	For
MUTUAL FUND SERIES TRUST	257,218	0	For
American Century	0	239,067	Abstain
MARSICO INVESTMENT FUND	219,460	0	For
Jackson National	113,073	106,099	For
Goldman Sachs	203,029	2,940	For
MFS	0	187,214	Abstain
Bridge Builder Trust	28,464	112,511	Abstain
Equitable	100,505	36,639	For

Showing the 25 largest of 117 asset managers. See all 117 in the interactive database.

4. To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Mark A. Goldsmith, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 157,681,628WITHHELD: 3,160,076

Revolution Medicines, Inc.’s own tally for this item (“Elect Director: Mark A. Goldsmith, M.D., Ph.D.”): 157,681,628 for, 3,160,076 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 200,178,626 outstanding shares: 79% for, 2% withheld (80% of the company cast a for/withheld vote).

The 117 asset managers below cast 100% of the shares they voted on this item FOR (51,605,888 for, 0 against).

FOR 99%

FOR: 51,605,888 (98.9%)ABSTAIN: 567,935 (1.1%)NOT VOTED: 235 (0.0%)

Largest asset managers voting on “To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his suc” at Revolution Medicines, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	19,362,706	11	For
Fidelity	9,665,843	0	For
JANUS INVESTMENT FUND	5,021,654	0	For
BlackRock	4,194,817	0	For
T. Rowe Price	2,563,078	0	For
Charles Schwab	1,843,991	0	For
State Street	940,888	9	For
Columbia Threadneedle	869,224	0	For
Capital Group	794,687	0	For
Lord Abbett	707,700	0	For
Franklin Custodian Funds	400,000	0	For
Dimensional	0	350,840	Abstain
Victory Capital	324,634	0	For
TIAA	313,907	0	For
FRANKLIN STRATEGIC SERIES	287,036	0	For
JANUS ASPEN SERIES	271,217	0	For
Invesco	260,273	0	For
MUTUAL FUND SERIES TRUST	257,218	0	For
American Century	239,067	0	For
MARSICO INVESTMENT FUND	219,460	0	For
Jackson National	216,063	3,109	For
Goldman Sachs	205,969	0	For
MFS	187,214	0	For
Bridge Builder Trust	140,975	0	For
Equitable	100,505	36,639	For

Showing the 25 largest of 117 asset managers. See all 117 in the interactive database.

5. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

79% fund support · no official result

FOR 79%AGAINST 21%

The 19 asset managers below cast 79% of the shares they voted on this item FOR (222,426 for, 59,476 against).

FOR: 222,426 (78.9%)AGAINST: 59,476 (21.1%)NO VOTE: 7 (0.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Revolution Medicines, Inc., 2025-2026
Asset manager	For	Against	Vote
Eversept Partners, LP	127,289	0	For
Cardano Risk Management B.V.	0	41,212	Against
Birnam Oak Advisors, LP	27,304	0	For
Granahan Investment Management, LLC	26,048	0	For
NORDEA INVESTMENT MANAGEMENT AB	0	18,264	Against
Metzler Asset Management GmbH	11,731	0	For
Wilshire Advisors LLC	9,812	0	For
Life Cycle Investment Partners Ltd	7,302	0	For
ALGERT GLOBAL LLC	6,905	0	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	2,170	0	For
Osmosis Investment Management UK Ltd	2,021	0	For
Vinva Investment Management Ltd	1,562	0	For
TD Waterhouse Canada Inc.	270	0	For
Impact Investors, Inc	0	0	No Vote
Coyle Financial Counsel LLC	6	0	For
Milliman Funds Trust	5	0	For
Convergence Investment Partners, LLC	1	0	For
Torrey Growth & Income Advisors	0	0	--
Trivant Custom Portfolio Group, LLC	0	0	--

6. To elect two Class Il directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected:

DIRECTOR ELECTIONS

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (51,103 for, 0 against).

FOR: 51,103 (100.0%)

Largest asset managers voting on “To elect two Class Il directors to hold office until the 2029 Annual Meeting of Stockholders or until his succ” at Revolution Medicines, Inc., 2025-2026
Asset manager	For	Vote
Advisors' Inner Circle Fund III	38,164	For
Franklin Alternative Strategies Funds	6,411	For
Putnam	6,411	For
Meeder Funds	117	For

7. To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (18 for, 0 against).

FOR: 18 (100.0%)

Largest asset managers voting on “To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives” at Revolution Medicines, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Modern Wealth Management, LLC	9	0	0	0	For
Tandem Financial, LLC	9	0	0	0	For

8. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission;("Say-on-Pay").

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

ABSTAIN 99.9%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (46 for, 0 against).

FOR: 46 (0.0%)ABSTAIN: 357,791 (100.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as di” at Revolution Medicines, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
GENERAL ATLANTIC, L.P.	0	0	357,791	0	Abstain
Column Group LLC	46	0	0	0	For

Largest Revolution Medicines, Inc. shareholders voting in 2025-2026

Ranked by the number of Revolution Medicines, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 200,178,626 shares outstanding at the time of that meeting.

Top Revolution Medicines, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Janus Henderson	10.82%
2	Vanguard	10.41%
3	Fidelity	10.02%
4	FARALLON CAPITAL MANAGEMENT, L.L.C.	7.06%
5	BlackRock	5.48%
6	T. Rowe Price	3.21%
7	Darwin Global Management, Ltd.	2.89%
8	Paradigm Biocapital Advisors LP	2.54%
9	JANUS INVESTMENT FUND	2.51%
10	Wellington	2.20%

Reported Revolution Medicines, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Revolution Medicines, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	8.35%	13F
Entities affiliated with Farallon Capital Partners, L.P.	7.23%	DEF14A
Baker Bros. Advisors LP	5.72%	13G
Entities affiliated with Janus Henderson Group PLC	5.67%	DEF14A
BlackRock	5.60%	13F
JANUS HENDERSON GROUP PLC	4.88%	13G
FMR (Fidelity)	4.23%	13F
Thilo Schroeder, Ph.D.	3.80%	DEF14A
Wellington Management	3.01%	13F
State Street	2.20%	13F

Percentages above are of 200,178,626 shares outstanding, as reported by Revolution Medicines, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Revolution Medicines, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Revolution Medicines, Inc.'s shareholder meeting held 2026-06-18, in the 2025-2026 proxy season, 527 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,571 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Revolution Medicines, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — the reporting funds cast 97% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Revolution Medicines, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).